Faropenem daloxate (Standard)

Faropenem daloxate (Faropenem medoxil) (Standard) is the analytical standard of Faropenem daloxate (Faropenem medoxil) . This product is intended for research and analytical applications. Faropenem daloxate is an orally active beta-lactam antibiotic. Faropenem daloxate has excellent in vitro activity against Streptococcus pneumonia, Haemophilus influenza, and other key pathogens implicated in acute bacterial rhino sinusitis. Faropenem daloxate can be studied in research for respiratory pathogens and acute bacterial sinusitis[1][2][3][4][5].

Product Specifications

CAS Number

[141702-36-5]

Product Name Alternative

Faropenem medoxil (Standard)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Reference Standards

Related Pathways

Anti-infection; Others

Field of Research

Infection

Smiles

O=C(N1[C@@]2(SC([C@@H]3OCCC3)=C1C(OCC4=C(OC(O4)=O)C)=O)[H])[C@]2([H])[C@H](O)C

Molecular Formula

C17H19NO8S

Molecular Weight

397.40

References & Citations

[1]Faqi AS, Lanphear C, Gill S, Colagiovanni DB.Juvenile toxicity study of faropenem medoxomil in beagle puppies.Reprod Toxicol. 2010 Dec;30 (4) :619-24. Epub 2010 Aug 11.|[2]Hadley JA, Tillotson GS, Tosiello R, Echols RM.Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.Expert Rev Anti Infect Ther. 2006 Dec;4 (6) :923-37.|[3]Siegert R, Berg O, Gehanno P, Leiberman A, Martinkenas JL, Nikolaidis P, Arvis P, Alefelder M, Reimnitz P.Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.Eur Arch Otorhinolaryngol. 2003 Apr;260 (4) :186-94. Epub 2002 Oct 11.|[4]Upchurch J, Rosemore M, Tosiello R, Kowalsky S, Echols R.Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis.Otolaryngol Head Neck Surg. 2006 Oct;135 (4) :511-7.|[5]Gettig, Jacob P.; Crank, Christopher W.; Philbrik, Alexander H. Faropenem medoxomil. Annals of Pharmacotherapy (2008), 42 (1), 80-90.